Vyndamax is owned by Foldrx Pharms.
Vyndamax contains Tafamidis.
Vyndamax has a total of 3 drug patents out of which 0 drug patents have expired.
Vyndamax was authorised for market use on 03 May, 2019.
Vyndamax is available in capsule;oral dosage forms.
Vyndamax can be used as treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm).
Drug patent challenges can be filed against Vyndamax from 2023-05-04.
The generics of Vyndamax are possible to be released after 31 August, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7214695||FOLDRX PHARMS||Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding|| |
(1 year, 25 days from now)
|US9770441||FOLDRX PHARMS||Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole|| |
(12 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7214696||FOLDRX PHARMS||Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding|| |
(8 months from now)
|New Chemical Entity Exclusivity (NCE)||May 3, 2024|
|Orphan Drug Exclusivity (ODE)||May 3, 2026|
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 2023-05-04
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic